Quanterix
Quanterix is committed to transforming healthcare through ultrasensitive biomarker detection technology, Simoa®, which enables early disease detection, better prognoses, and improved treatment methods across various therapeutic areas including neurology, infectious disease, oncology, inflammation, and cardiology. The company provides advanced immunoassay platforms, assay kits, and custom development services to support research and clinical diagnostics. With a focus on innovation, diversity, and high-performance culture, Quanterix empowers researchers and clinicians worldwide to accelerate breakthroughs in precision health.
Industries
Nr. of Employees
large (251-1000)
Quanterix
900 Middlesex TPKE, Billerica, MA 01821, USA
Patents
Ultra-sensitive detection of molecules or particles using beads or other capture objects
US-12235267-B2
View DetailsMethods and systems for extending dynamic range in assays for the detection of molecules or particles
US-12019072-B2
View DetailsSystems, devices, and methods for ultra-sensitive detection of molecules or particles
US-11977087-B2
View Details
Ultra-sensitive detection of molecules or particles using beads or other capture objects
US-12235267-B2
View DetailsMethods and systems for extending dynamic range in assays for the detection of molecules or particles
US-12019072-B2
View DetailsSystems, devices, and methods for ultra-sensitive detection of molecules or particles
US-11977087-B2
View DetailsProducts
Automated bead-based digital immunoassay analyzer (fully automated)
A fully automated analyzer for bead-based digital immunoassays supporting walk-away operation, high sensitivity single-molecule detection, and features to assist electronic record management.
Benchtop single-molecule detection instrument (semi-automated)
Compact benchtop instrument providing single-molecule detection with semi-automated workflows, optimized for low-volume multiplex assays.
Planar array imaging and analysis system (high-plex)
Benchtop planar array imaging system for high-plex multiplex assays with high-resolution optics and ML-optimized image analysis to maximize dynamic range and signal-to-noise.
Microarray arrayer for DNA and protein printing
Microarray printing system for producing high-density arrays of DNA, proteins, cell lysates and other sample types using controlled deposition methods.
Standardized dried blood/plasma spot extraction kit
Kit and protocol for standardized extraction of analytes from dried blood spots and dried plasma spots for compatibility with ultrasensitive immunoassays.
Multiplex cytokine assay panels (research kits)
Multiplex cytokine panels (e.g., 4‑plex) designed for low sample volumes and compatibility with automated analyzers to profile multiple cytokines in immunology and infectious disease research.
Automated bead-based digital immunoassay analyzer (fully automated)
A fully automated analyzer for bead-based digital immunoassays supporting walk-away operation, high sensitivity single-molecule detection, and features to assist electronic record management.
Benchtop single-molecule detection instrument (semi-automated)
Compact benchtop instrument providing single-molecule detection with semi-automated workflows, optimized for low-volume multiplex assays.
Planar array imaging and analysis system (high-plex)
Benchtop planar array imaging system for high-plex multiplex assays with high-resolution optics and ML-optimized image analysis to maximize dynamic range and signal-to-noise.
Microarray arrayer for DNA and protein printing
Microarray printing system for producing high-density arrays of DNA, proteins, cell lysates and other sample types using controlled deposition methods.
Standardized dried blood/plasma spot extraction kit
Kit and protocol for standardized extraction of analytes from dried blood spots and dried plasma spots for compatibility with ultrasensitive immunoassays.
Multiplex cytokine assay panels (research kits)
Multiplex cytokine panels (e.g., 4‑plex) designed for low sample volumes and compatibility with automated analyzers to profile multiple cytokines in immunology and infectious disease research.
Services
Clinical and research sample testing, custom biomarker assays, and regulated data reporting performed in a CLIA-licensed laboratory environment.
Assay design, optimization, and transfer services for low-abundance protein and circulating nucleic acid targets, including guidance on helper-bead usage, bead concentrations, and assay validation metrics.
Provision of monodisperse dye-encoded and magnetic beads with tunable size, density, and surface chemistries for reagent manufacturers and diagnostic kit OEMs.
Clinical and research sample testing, custom biomarker assays, and regulated data reporting performed in a CLIA-licensed laboratory environment.
Assay design, optimization, and transfer services for low-abundance protein and circulating nucleic acid targets, including guidance on helper-bead usage, bead concentrations, and assay validation metrics.
Provision of monodisperse dye-encoded and magnetic beads with tunable size, density, and surface chemistries for reagent manufacturers and diagnostic kit OEMs.
Expertise Areas
- Neurology plasma and CSF biomarker measurement
- Oncology biomarker quantitation and multiplex panels
- Immunology and cytokine profiling
- Infectious disease serology and antigen detection (research use)
Key Technologies
- Digital single-molecule immunoassay (digital ELISA)
- Bead-based multiplex immunoassays (dye-encoded and magnetic beads)
- Planar array high-plex imaging
- Microarray printing / arrayer technology
News & Updates
Quanterix will be exhibiting at AAIC 2025 in Toronto, Canada.
Quanterix to present at the conference.
Quanterix releases its financial results for the first quarter of 2025.
Quanterix discusses the future of blood tests in neurological diseases and the approval of Qalsody, a drug for ALS that uses blood biomarkers.
Quanterix will be exhibiting at AAIC 2025 in Toronto, Canada.
Quanterix to present at the conference.
Quanterix releases its financial results for the first quarter of 2025.
Quanterix discusses the future of blood tests in neurological diseases and the approval of Qalsody, a drug for ALS that uses blood biomarkers.